MedTrace Logo

Effects of Novel Estrogens on Glucose and Lipids in Postmenopausal Prediabetic Women Veterans

NCT05073237 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-05-10

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of a novel menopause hormone therapy on blood sugar (glucose) and blood and liver fats (lipids) in obese menopausal women Veterans.

Conditions

Interventions

OTHER

Placebo

Daily placebo tablet

DRUG

conjugated estrogens/bazedoxifene (CE/BZA)

Participants assigned to CE/BZA will receive a daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20mg.

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Dragana Lovre, MD · Southeast Louisiana Veterans Health Care System, New Orleans, LA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-08
Primary Completion
2024-04-08
Completion
2024-04-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05073237 on ClinicalTrials.gov